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Summary
Objectives: A retrospective study was conducted to elucidate contributing factors
on the outcome of patients with vasospastic angina.
Subjects and methods: Two hundred ninety-two patients with angina in whom
coronary vasospasm was documented were followed up (mean 4.3± 3.6 years) to
determine the relationship between the occurrence of cardiovascular events with
available clinical factors including therapeutic drugs. Cardiovascular events were
deﬁned as fatal and non-fatal cardiovascular disorder events.
Results: Several clinical variables including age, elevated creatinine level, low high-
density lipoprotein (HDL) cholesterol level, presence of severe coronary artery
stenosis, low left ventricular ejection fraction, low cardiac index (CI), large left
ventricular mass, and use of beta-blockers proved to be signiﬁcant risk fac-
tors for cardiovascular events. Further analysis by a stepwise regression analysis
UP
LIC
AT
Erevealed that, older age (hazard ratio (HR) = 1.42), low HDL cholesterol level
(HR = 0.877), presence of severe coronary artery stenosis (HR = 49.32), and decreased
CI (HR = 14.18) proved to be independent prognostic factors. Ca antagonists were
prescribed to 261 patients (89.4%). Among four Ca antagonists, there were signif-
icant differences in the frequency of cardiovascular events (2.6% with benidipine,
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4.2% with nifedipine, 6.0% with diltiazem, 23.1% with amlodipine; amlodipine vs.
benidipine, P < 0.05) although the background characteristics of the four different
patient groups were non-equivalent.
Conclusion: These results indicate that the morbidity of patients with vasospastic
angina increased with older age, lower CI or HDL cholesterol, and presence of severe
coronary artery stenosis, and that treatment with benidipine appeared to reduce
cardiovascular events in patients with vasospastic angina.
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vasospastic angina, the following variables were
investigated from the medical record as patients’
characteristics: gender, age, body mass index (BMI),© 2008 Japanese Colleg
reserved.
ntroduction
oronary artery spasm is involved in various coro-
ary arterial diseases, such as vasospastic angina,
yocardial infarction and sudden death. Coro-
ary vasospasm is caused by abnormal contraction
f coronary vascular smooth muscles, and one
ause of its occurrence seems to be vascular
ndothelial dysfunction [1]. It is believed that
ndothelial dysfunction including decreased nitric
xide production (NO) [2,3] leads to abnormalities
n the maintenance of vascular tonus, and as a
esult, sympathetic nerve activation at rest in the
arly morning, cold stimuli, excessive alcohol con-
umption, and other provocative factors result in
bnormal contraction of coronary vascular smooth
uscles.
Some researchers have reported the incidence of
atients with vasospastic angina in Japan. Pristipino
t al. compared the response to acetylcholine
n infarct-related lesions and non-infarct-related
esions between Japanese and Caucasian patients
ith acute myocardial infarction, and demon-
trated that coronary spasm is three times more
requent in the Japanese than in the Caucasians [4].
n a multi-center study performing a spasm provo-
ation test by Yasue et al., as many as 40—60%
f patients with angina had coronary vasospasm.
lthough the frequency is different among areas or
nstitutions, vasospastic angina may account for a
ery high proportion of angina types [5—7]. High
requency of coronary vasospasm in the Japanese
s attributed to racial differences in the involved
enes [8—11].
In general Ca antagonists are useful for the
ong-term outcome of vasospastic angina [12]. How-
ver, sudden death or myocardial infarction may
ccur in some patients with active vasospasm, and
hey should be carefully followed up. Coronary
asospasm is most commonly treated with contin-
ous oral administration of coronary vasodilators
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PLepresented by Ca antagonists. On the other hand,
otwithstanding the large number of patients with
asospastic angina, reports are limited on the risk
actors for cardiovascular diseases and the choice
f
i
o
iCardiology. Published by Elsevier Ireland Ltd. All rights
f therapeutic drugs improving long-term survival
12—14], and further studies are required.
We therefore retrospectively studied the effects
f patients’ characteristics and therapeutic drugs
n the incidence of cardiovascular events in those
ospitalized in Fukuoka University Chikushi Hospital
nd diagnosed with vasospastic angina.
atients and methods
ubjects and procedures
ut of 387 patients with vasospastic angina treated
t the cardiovascular division of our hospital from
ay 1987 to June 2006, 292 could be followed up
nd were enrolled in the study. Coronary arteri-
graphy was performed in all patients with chest
ain attacks at rest. The administration of coro-
ary vasodilators including Ca antagonists and NO
onors was stopped before coronary arteriography.
atients were diagnosed with vasospastic angina
hen spasm was provoked by administering acetyl-
holine into the coronary artery. Before the spasm
rovocation test with acetylcholine, a control arte-
iography was performed. Acetylcholine was then
njected from the same angle into the right coro-
ary artery at 10g, 30g, or 50g and into the
eft coronary artery at 10g, 30g, 50g, or 100g
ach over 1min. Coronary spasm was deﬁned as
otal or subtotal obstruction (i.e. >99%) associated
ith an attack of chest pain, ischemic ST-segment
hanges on the electrocardiogram (ECG), or both
15]. The test was discontinued when coronary
pasm was induced.
Considering the results of a questionnaire and
easurements of blood biochemical parameters
nd cardiac function at the time of diagnosis of
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Eamily history of ischemic heart diseases, smok-
ng history, drinking history, complications (history
f hypertension, dyslipidemia, diabetes mellitus,
mpaired glucose tolerance, myocardial infarction,
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and cerebrovascular disorder), coronary artery
stenosis, blood biochemical analysis [blood glu-
cose, total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglyceride, uric acid, brain natri-
uretic peptide (BNP), creatinine, C-reactive protein
(CRP), white blood cell count], and cardiac func-
tion tests [left ventricular ejection fraction (LVEF),
cardiac index (CI), left ventricular end-diastolic
dimension (LVdD), left ventricular mass (LVmass)].
Complications were diagnosed according to the
following guidelines: ‘‘Japanese Society of Hyper-
tension Guidelines’’ for hypertension, ‘‘Japan
Atherosclerosis Society Guidelines’’ for dyslipi-
demia, ‘‘Japan Diabetes Society Guidelines’’ for
diabetes and abnormal glucose tolerance, and
‘‘Japanese Circulation Society Guidelines’’ for
ischemic heart diseases. Stenosis of the coronary
artery was evaluated by coronary arteriography
after nitroglycerine injection according to the
American Heart Association (AHA) classiﬁcation.
Stenosis of >75% in one or more branches of any
of the right coronary artery (RCA), left main trunk
artery (LMT), left circumﬂex artery (LCX), or left
anterior descending artery (LAD) was regarded as
signiﬁcant coronary artery stenosis. Oral medi-
cations such as Ca antagonists, statins, nitrates,
aspirin, nicorandil, and beta-blockers were also
investigated.
Subjects were followed up by mail or phone
from the time of diagnosis with vasospastic angina
to October 1, 2006 to investigate survival and
occurrence of cardiovascular events. Cardiovascu-
lar events were deﬁned as fatal cardiovascular
disorder and non-fatal events. Fatal cardiovascu-
lar disorder included death due to sudden death,
acute myocardial infarction, cerebrovascular disor-
der, heart failure, and aortic aneurysm. Non-fatal
events included occurrence of acute myocardial
infarction, cerebrovascular disorder, heart failure,
aortic aneurysm, renal failure, and obstructive
atherosclerosis, as well as undergoing cardiac
surgery such as percutaneous coronary intervention
(PCI) and coronary artery bypass grafting (CABG).
Statistical analysis
All data were expressed with mean± standard
deviation (S.D.) and statistically analyzed using
computer software, SPSS for Windows, Ver.11.0.1
(SPSS Japan Inc., Tokyo, Japan). The level of sig-
UP
Lniﬁcance was set at 0.05 (two-tailed). Differences
were considered statistically signiﬁcant when the P-
value was less than 0.05. Patients’ characteristics
that may affect the outcome of vasospastic angina
and the efﬁcacy of therapeutic drugs were analyzed
v
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y univariate logistic regression and Cox regression
o calculate odds and hazard ratios, respectively.
he cardiovascular event-free curves were plotted
y the Kaplan—Meier method and compared using
he log-rank test.
esults
linical features of patients
total of 292 of 382 patients (75.4%) could be fol-
owed up and the mean follow-up was 4.1± 3.6
ears. Table 1 shows the characteristics of the
hole population and of patients stratiﬁed by the
resence or absence of cardiovascular events. The
ean age was 64.1 years, the male to female ratio
as 59 to 41, and 34% and 55% of patients had
moking and drinking habits, respectively. The most
ommon complications were hypertension and dys-
ipidemia in 45% and diabetes in 15% (17% including
bnormal glucose tolerance).
Cardiovascular events occurred in 16 patients
5.5%), fatal cardiovascular disease in 1 and non-
atal cardiovascular events in 15. Patients who
uffered from cardiovascular events were older and
ad lower HDL cholesterol level and higher cre-
tinine level than event-free patients. They also
howed lower cardiac function (LVEF, CI) and higher
ncidence of coronary artery stenosis. The use of
eta-blockers was associated with a higher fre-
uency of cardiovascular events. Other drugs (Ca
ntagonists, statins, nitrates, aspirin, nicorandil)
id not affect the outcome.
rognostic factors in patients with
asospastic angina
he relationship between patients’ characteristic
nd cardiovascular events shown in Table 1 was ana-
yzed by univariate logistic regression. The eight
ariables shown in Table 2 had a signiﬁcant relation-
hip with cardiovascular events. In addition to these
haracteristics, the factors reported in the litera-
ure to predict the outcome of vasospastic angina
gender, hypertension, smoking habit, diabetes and
bnormal glucose tolerance, Ca antagonists) and
ther therapeutic drugs (statins, nitrates, aspirin,
icorandil) were included in the Cox regression
nalysis. The results are shown in Table 2. Four
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Eariables, coronary artery stenosis, decreased CI,
igh age, and low HDL cholesterol level, were
ndependent prognostic factors for cardiovascular
vents in vasospastic angina, and the hazard ratios
ere higher in this order. The Kaplan—Meier curves
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Table 1 Patients’ characteristics.
Whole population Cardiovascular events P-value
(+) (−)
No. of patients 292 16 276
Characteristics
Gender (men), n (%) 172(59%) 10(63%) 162(59%) n.s.
Age (when diagnosed at
catheter insertion)
64± 10 71± 9 64± 10 <0.05
BMI 24± 3 23± 2 24± 3 n.s.
Family history of ischemic
cardiac diseases, n (%)
45 (15%) 3 (19%) 42 (15%) n.s.
Smoking, n (%) 100 (34%) 5 (31%) 95 (34%) n.s.
Drinking, n (%) 160 (55%) 9 (56%) 151 (55%) n.s.
Complications
Hypertension, n (%) 132 (45%) 11 (69%) 121 (44%) n.s.
Dyslipidemia, n (%) 130 (45%) 6 (38%) 124 (45%) n.s.
Diabetes mellitus, n (%) 45 (15%) 1 (6%) 44 (16%) n.s.
Impaired glucose tolerance,
n (%)
5 (2%) 1 (6%) 4 (1%) n.s.
History of myocardial
infarction, n (%)
13 (4%) 1 (6%) 12 (4%) n.s.
History of cerebrovascular
disorder, n (%)
11 (4%) 1 (6%) 10 (4%) n.s.
Cardiac function
LVEF, % 72± 11 64± 16 72± 11 <0.05
CI, l/min/m2 3.3± 0.9 2.9± 1.1 3.3± 0.9 <0.05
LVDd, mm 48± 7 50± 6 48± 7 n.s.
LVmass, g 159± 57 195± 49 157± 56 <0.05
Signiﬁcant stenosis of the
coronary artery, n (%)
28 (10%) 5 (31%) 23 (8%) <0.05
Blood biochemical parameters
Glucose, mg/dl 103± 35 96± 13 103± 36 n.s.
Total-C, mg/dl 197± 34 196± 35 197± 34 n.s.
HDL-C, mg/dl 54± 16 43± 11 54± 16 <0.05
LDL-C, mg/dl 119± 31 127± 33 118± 31 n.s.
TG, mg/dl 130± 79 151± 57 129± 80 n.s.
Uric acid, mg/dl 5.6± 1.7 6.3± 1.8 5.6± 1.6 n.s.
BNP, pg/ml 100± 114 129± 147 97± 113 n.s.
Creatinine, mg/dl 0.8± 0.2 1.0± 0.3 0.8± 0.2 <0.05
CRP, mg/dl 0.3± 0.9 0.1± 0.1 0.3± 0.9 n.s.
WBC, /l 5897± 1990 6328± 1551 5875± 2010 n.s.
Therapeutic drugs
Ca antagonists 261 (89%) 14 (88%) 247 (89%) n.s.
Statin, n (%) 71 (24%) 3 (19%) 68 (25%) n.s.
Nitrates, n (%) 60 (21%) 2 (13%) 58 (21%) n.s.
Aspirin, n (%) 60 (21%) 4 (25%) 56 (20%) n.s.
Nicorandil, n (%) 59 (20%) 4 (25%) 55 (20%) n.s.
Beta-blockers, n (%) 9 (3%) 2 (13%) 7(3%) <0.05
Values are mean± S.D., or frequency counts, as appropriate. BMI, body mass index; LVEF, left ventricular ejection fraction;
CI, cardiac index; LVDd, left ventricular diastolic dimension; LVmass, left ventricular mass; Total-C, total cholesterol; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BNP, plasma brain natriuretic
peptide; CRP, C-reactive protein; WBC, white blood cell count.
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Table 2 Odds ratios by univariate logistic regression analysis and hazard ratios by Cox regression analysis of
patient’s characteristics.
Univariate logistic analysis Cox regression analysis
Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Lower Upper Lower Upper
LVEF (<45%) 9.2 2.1 40 0.003 29.5 0.5 1803 0.11
CI (<2.5 l/min/m2) 4.8 1.7 13.8 0.004 14.2 1.3 153 0.03
Signiﬁcant stenosis 5.0 1.6 15.6 0.006 49.3 2.1 1184 0.02
Age 1.1 1.0 1.2 0.007 1.4 1.1 1.9 0.01
Creatinine 6.6 1.4 30.9 0.02 11.5 0.2 800 0.26
HDL-C 0.9 0.9 1.0 0.02 0.9 0.8 1.0 0.01
LVmass 5.8 1.3 26.9 0.02 1.4 0.1 21.5 0.79
0
L-C,
n
p
T
aBeta-blockers 5.5 1.0 28.9
LVEF, left ventricular ejection fraction; CI, cardiac index; HD
mass.
for cardiovascular event-free survival are shown in
Fig. 1 for these four variables.Effects of Ca antagonists on long-term
survival in patients with vasospatic angina
Ca antagonists were prescribed to 89.4% of
patients; diltiazem to 151, benidipine to 78,
f
m
n
y
Figure 1 Effects of coronary artery stenosis (A), cardiac index
cardiovascular events in patients with vasospastic angina.
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high-density lipoprotein cholesterol; LVmass, left ventricular
ifedipine to 24, and amlodipine to 13. Eleven
atients received more than two Ca antagonists.
he mean dose was 149.4± 50.3mg for dilti-
zem, 4.1± 1.5mg for benidipine, 30.0± 10.3mg
E
or nifedipine, and 5.0mg for amlodipine. The
ean follow-up of patients receiving Ca antago-
ists was 4.3± 4.0 years for diltiazem, 3.5± 2.9
ears for benidipine, 3.6± 3.5 years for nifedip-
(B), age (C), and HDL cholesterol (D) on survival without
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Table 3 Frequency of cardiovascular events by Ca antagonist.
Diltiazem Benidipine Nifedipine Amlodipine
No. of patients 151 78 24 13
Observation period, years 4.3± 4.0 3.5± 2.9 3.6± 3.5 3.6± 3.5
Cardiovascular events, n (%) 9 (6%)
Odds ratio 1.2
P-value 0.71
Figure 2 Effects of calcium channel blockers on survival
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Stenosis of the coronary artery has been reportedithout cardiovascular events in patients with vasospas-
ic angina.
ne, and 3.6± 3.5 years for amlodipine. There were
o signiﬁcant differences in the rates of other
rug treatment including anti-hypertensive, anti-
yslipidemia, anti-coagulants, etc.
Table 3 shows the incidence of cardiovascular
vents by Ca antagonists. The frequency of car-
iovascular events was 2.6% in the group treated
ith benidipine, 4.2% with nifedipine, 6.0% with
iltiazem, and 23.1% with amlodipine.
Table 4 summarizes the background charac-
eristics of four different patient groups treated
ith four different Ca antagonists (diltiazem, beni-
ipine, nifedipine, and amlodipine). There were
igniﬁcant differences in the prevalence of hyper-
ension, impaired glucose tolerance, and low
DL-cholesterol among the four groups, although
he number of patients categorized into four dif-
erent groups were not equivalent. In order to
xamine the difference of the four different Ca
ntagonists, Kaplan—Meier analysis for cardiovas-
ular event-free survival was performed (Fig. 2).
enidipine and diltiazem provided an equiva-
ent beneﬁt to suppress cardiovascular events in
atients with vasospastic angina, while amlodip-
ne showed a signiﬁcantly worse outcome compared
o benidipine. Namely, the occurrence of cardio-
DU
PLascular events was signiﬁcantly higher in the
mlodipine group compared to the benidipine group
P < 0.05).
t
w
Y2 (2.6%) 1 (4.2%) 3 (23.1%)
0.4 0.7 6.1
0.20 0.77 0.01
iscussion
linical features and prognostic factors in
atients with vasospastic angina
ong-term follow-up for more than 4 years in 292
atients with vasospatic angina revealed that high
ge, low serum HDL cholesterol level, presence of
evere coronary artery stenosis, and decreased CI
ere signiﬁcant detrimental prognostic factors.
This study demonstrated for the ﬁrst time that
ecreased CI is an independent poor prognos-
ic factor, in addition to severe stenosis of the
oronary artery and high age which have been
reviously reported [14,16]. It also showed that
low HDL cholesterol level is a risk factor for
oor outcome. Previous reports [16,17] suggested
relationship between dyslipidemia and coronary
pasm. Yamagishi et al. reported that a high LDL
holesterol level (>140mg/dl) is a poor prognostic
actor in patients with vasospastic angina with-
ut severe coronary artery stenosis [16] and Miwa
eported low HDL cholesterol levels in patients with
asospastic angina [17]. The relationship between
oronary spasm with triglycerides and obesity was
ot demonstrated in this study, but it was possible
hat abnormal lipid metabolism including low HDL
holesterol level caused endothelial dysfunction,
therosclerosis, stenosis of the coronary artery, and
onsequently cardiovascular events.
Our data revealed that low CI was an inde-
endent predictive risk factor for cardiovascular
vents in patients with vasospastic angina. It has
een generally considered that vasospasm is asso-
iated with temporal, but not chronic, decrease
n cardiac output. Although short-term myocardial
schemia caused by vasospasm may cause a tem-
oral myocardial stunning and low output status,
he observed low CI in the present study was not
ransient and, therefore, was not directly caused by
asospasm, rather by other preexisting confounding
actors such as previous myocardial ischemia and
ypertensive heart failure.
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hich is in accordance with our present results.
amagishi et al. have reported that coronary artery
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Table 4 Comparison of patients’ characteristics.
Diltiazem Benidipine Nifedipine Amlodipine P-value
No. of patients 139 70 22 13
Characteristics
Gender (men), n (%) 84 (60%) 41 (59%) 14 (64%) 9 (75%) n.s.
Age (when diagnosed at catheter insertion) 63 ± 11 64 ± 10 68 ± 9 66 ± 7 n.s.
BMI 23 ± 3 24 ± 4 24 ± 3 25 ± 3 n.s.
Family history of ischemic cardiac diseases, n (%) 24 (21%) 8 (14%) 6 (33%) 1 (11%) n.s.
Smoking, n (%) 42 (30%) 30 (43%) 6 (27%) 7 (58%) n.s.
Drinking, n (%) 77 (56%) 42 (60%) 12 (55%) 7 (58%) n.s.
Complications
Hypertension, n (%) 48 (34%) 33 (47%) 17 (77%) 12 (100%) <0.0001
Dyslipidemia, n (%) 61 (44%) 35 (50%) 11 (50%) 2 (17%) n.s.
Diabetes mellitus, n (%) 21 (15%) 8 (11%) 6 (27%) 1 (8%) n.s.
Impaired glucose tolerance, n (%) 0 (0%) 1 (1%) 2 (9%) 2 (17%) <0.05
History of myocardial infarction, n (%) 8 (6%) 4 (6%) 0 (0%) 0 (0%) n.s.
History of cerebrovascular disorder, n (%) 6 (4%) 2 (3%) 1 (5%) 0 (0%) n.s.
Cardiac function
LVEF, % 71 ± 11 72 ± 12 73 ± 10 73 ± 14 n.s.
CI, l/min/m2 3.3± 0.9 3.1± 0.8 3.6± 1.1 3.0± 0.6 n.s.
LVDd, mm 48 ± 6 48 ± 9 48 ± 5 52 ± 4 n.s.
LVmass, g 181 ± 66 183 ± 83 176 ± 53 209 ± 59 n.s.
Signiﬁcant stenosis of the coronary artery, n (%) 7 (5%) 10 (14%) 2 (9%) 2 (17%) n.s.
Blood biochemical parameters
Glucose, mg/dl 99 ± 26 104 ± 28 124 ± 85 99 ± 13 n.s.
Total-C, mg/dl 196 ± 32 201 ± 35 196 ± 40 184 ± 19 n.s.
HDL-C, mg/dl 52 ± 15 57 ± 17 50 ± 13 44 ± 12 <0.05
LDL-C, mg/dl 118 ± 30 121 ± 35 117 ± 35 111 ± 21 n.s.
TG, mg/dl 129 ± 77 128 ± 89 141 ± 88 146 ± 67 n.s.
Uric acid, mg/dl 5.5± 1.5 5.7± 1.9 5.8± 2.1 6.4± 0.7 n.s.
BNP, pg/ml 90 ± 104 190 ± 196 58 ± 32 27 ± 0.1 n.s.
Creatinine, mg/dl 0.79± 0.19 0.81± 0.30 0.88±0.25 0.82± 0.19 n.s.
CRP, mg/dl 0.2± 0.7 0.3± 0.7 0.8± 2.3 0.1± 0.1 n.s.
WBC, /l 5870 ± 1784 5860 ± 2106 5782 ± 2021 5825 ± 1553 n.s.
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tenosis (more than 50% stenosis) in 256 patients
ith vasospastic angina is an independent con-
ributing factor for cardiovascular events (hazard
atio of 2.84) compared with patients without coro-
ary artery stenosis [16]. Kido et al. also reported
hat, in both sexes, the coronary sclerosis indices
n the vasospasm positive group were higher than
hose in the negative group [18]. Thus, signiﬁ-
ant coronary artery stenosis appears to be an
ndependent risk factor for cardiovascular events
n patients with vasospastic angina. The detailed
echanism of how coronary artery lesions affect
he long-term outcome of vasospastic angina has
ot yet been determined, but it is likely that a sig-
iﬁcant organic stenosis is linked with multiple risk
tratiﬁcation, such as aging, hypertension, dyslipi-
emia, and low HDL-cholesterol level. Our present
ata suggest that each of these risk factors was
lso an independent predictive factor for cardio-
ascular events in patients with vasospastic angina.
bviously, a future prospective study is necessary
o determine how severe coronary artery stenosis
s linked to cardiovascular events in patients with
asospastic angina.
Summarizing these ﬁndings, our data show that
o-existence of coronary artery spasm and steno-
is affects the long-term outcomes of vasospastic
ngina and their appropriate management is an
mportant factor to reduce cardiovascular events.
ffects of therapeutic drugs on long-term
urvival of patients with vasospastic angina
a antagonists were prescribed to about 90% of
atients enrolled in this study, and the use of
eta-blockers was limited. Yasue et al. reported
hat a beta-blocker, propranolol, was ineffective
nd the Ca antagonists diltiazem and nifedipine
ere effective to signiﬁcantly reduce exercise-
nduced attacks of coronary spasm [19] and that
a antagonists inhibited cardiac death and car-
iovascular events in 245 patients with variant
ngina [12]. Recent clinical studies investigated
he effects of Ca antagonists on the outcome of
atients with angina and coronary artery diseases
nd proved their usefulness [20,21]. As expected,
a antagonists were the most frequently prescribed
n the present study. On the other hand, use of
eta-blockers was associated with increased car-
iovascular events despite infrequent prescription
f the drugs.
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EThe important focus of the present study was
o compare the outcome effects of different Ca
ntagonists because the efﬁcacy of Ca antagonists
n vasospastic angina may differ from one drug to
nother. A few reports are available on which Ca
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antagonist is effective in patients with vasospasitic
angina pectoris. Ito et al. followed up 726 patients
with vasospastic angina and demonstrated that
survival without cardiovascular events with beni-
dipine was signiﬁcantly higher in comparison with
other Ca antagonists [14]. Sakata et al. reported
that benidipine was signiﬁcantly more effective to
inhibit cardiovascular events than diltiazem [22].
In the present study, the outcome differed depend-
ing on the choice of therapeutic drugs. As reported
by others, the frequency of cardiovascular events
was least with benidipine. Although the number of
amlodipine-treated patients was small, benidipine
was signiﬁcantly more effective in inhibiting cardio-
vascular events than amlodipine. The frequency of
cardiovascular events with benidipine was reported
by Ito et al. to be 2.0% (number of patients with
cardiovascular events/number of patients treated
with benidipine = 3/148), 2.9% (1/34) by Sakata et
al., and 2.6% (2/78) in this study. These results were
comparable with each other, and it appeared to be
conﬁrmative that benidipine improves the clinical
outcome of vasospastic angina.
Various mechanisms of action may be involved in
the effect of benidipine to improve the clinical out-
come. Results of the present study indicated that
decreased HDL cholesterol level or CI was associ-
ated with poor prognosis in vasospastic angina. In
fact, it has been reported that benidipine treat-
ment improves lipid metabolism manifested by
increase in HDL cholesterol level [23,24] and car-
diac function manifested by increase in CI [25].
It is also possible that benidipine retards the
progression of atherosclerosis. The progress of
atherosclerosis and promotion of oxidative stress
are known to be deeply implicated in increased
coronary spastic activity. Benidipine is superior
to other Ca antagonists in endothelial protection
[26,27], antioxidant properties [28], and anti-
inﬂammatory action [29].
Basic studies of benidipine indicated that this
compound more selectively acts on the coronary
vessels compared with other Ca antagonists [30,31]
and has a signiﬁcant anti-spastic effect [32]. Beni-
dipine was also reported to be useful in the clinical
setting to treat vasospastic angina which cannot
be sufﬁciently controlled with diltiazem [33]. Such
multiple actions of benidipine may decrease the
coronary spastic activity and inhibit cardiovascular
events in the long-term.
The interpretation of the present data that
DU
PLbenidipine appeared to be superior in the clinical
outcome of the patients with vasospastic angina
should be cautious because this study was a retro-
spective study. In fact, the patient characteristics
of each group treated with the different Ca antag-
d
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r
vS. Kodama et al.
nists were not equivalent. As shown in Table 4,
he prevalence of hypertension, impaired glucose
olerance, and low HDL-cholesterol in the nifedip-
ne or amlodipine groups was higher than that in
enidipine group, respectively. Those are impor-
ant risk factors for cardiovascular events. Among
hese risk factors, especially, the complication rate
f hypertension in the nifedipine or amlodipine
roups was signiﬁcantly higher than that in other
roups despite the non-equivalent patient numbers
n each group. It is a well known fact that hyperten-
ion itself causes endothelial dysfunction, vascular
emodeling, and the resultant systemic arterioscle-
osis, which may lead to subsequent cardiovascular
vents. In addition, the prevalence of impaired
lucose tolerance or low-HDL cholesterol, impor-
ant risk factors for cardiovascular events, were
lso signiﬁcantly different among the groups. These
ackground differences might be linked to the out-
ome difference among the four Ca antagonists. A
uture prospective study is warranted to examine
he difference among long-acting Ca antagonists in
erms of the suppressive effect of cardiovascular
vents in patients with vasospastic angina.
imitations
he interpretation of this retrospective, single-
nstitute, study is limited by relatively small sample
ize and inhomogeneous patients’ baseline char-
cteristics. The ﬁndings of several important risk
actors for patients with vasospastic angina and
he beneﬁcial effect of benidipine were inter-
sting and in accordance with several previous
eports. But, most of these studies were based
n retrospective analysis. A prospective random-
zed multi-center trial is deﬁnitively necessary to
dentify the long-term risk factors and the differ-
ntial beneﬁt among long-acting Ca antagonists in
atients with vasospastic angina.
onclusion
his retrospective study demonstrated that sev-
ral clinical conditions such as low HDL cholesterol
evel, presence of signiﬁcant coronary stenosis,
igher age, and low CI were important deter-
inants for long-term outcome in patients with
asosopastic angina. In addition, Ca antagonists are
ommonly used in this disease, but the outcome
IC
AT
Eiffers depending on the type of Ca antagonist.
enidipine and diltiazem were equally effective on
eduction of cardiovascular events in patients with
asospastic angina.
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